JW Life Science said on Feb. 2 that, on a consolidation basis, last year's operating profit was tentatively tallied at 33.3 billion won, down 7.12% from a year earlier.
Last year's sales rose 15.89% from a year earlier to 257.83 billion won, but net profit fell 34.63% to 28.75 billion won.
The company said that while sales of new products increased and subsidiary revenue grew, net profit declined from a year earlier due to higher one-off selling and administrative expenses such as service fees and a base effect from a temporary increase in derivative transaction gains in the previous year.
※ This article has been translated by AI. Share your feedback here.